This Article Full Text (PDF) All Versions of this Article: 1352458506069538v1 1352458506069538v2 1352458506069538v3 13/3/357    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goodman, A.D. Articles by Blight, A.R. Search for Related Content PubMed PubMed Citation Articles by Goodman, A.D. Articles by Blight, A.R. Social Bookmarking                   What's this?

Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study

Department of Neurology, University of Rochester, Rochester, NY 14642, USA,andrew_goodman@u rmc.rochester.edu

J.A. Cohen

Department of Neurology, Mellen Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA

A. Cross

Department of Neurology, Washington University, St Louis, MO 63110, USA

T. Vollmer

Department of Neurology, Yale University, New Haven, CT 06520, USA

M. Rizzo

Department of Neurology, Yale University, New Haven, CT 06520, USA

R. Cohen

Acorda Therapeutics, Inc., Hawthorne, NY 10532, USA

L. Marinucci

Acorda Therapeutics, Inc., Hawthorne, NY 10532, USA

A.R. Blight

Acorda Therapeutics, Inc., Hawthorne, NY 10532, USA

Objective To determine the safety of sustained-release 4-aminopyridine in subjects with mutiple sclerosis (MS) and to examine dose-related efficacy up to 40 mg twice daily.

Method Multicenter, randomized, double-blind, placebo-controlled, study. Following a 4-week baseline peroid, subjects were randomly assigned to receive Fampridine-SR (n=25, doses from 10 to 40 mg twice daily, increasing in 5 mg increments weekly) or placebo (n=11). A battery of assessments was performed weekly, including the MS Functional Composite (MSFC), fatigue questionnaires, and lower extremity manual muscle testing.

Results The most common adverse events were dizziness, insomnia, paresthesia, asthenia, nausea, headache, and tremor. Five subjects were discontinued from Fampridine-SR because of adverse events at doses greater than 25 mg, and these included convulsions in two subjects at doses of 30 and 35 mg twice daily. Improvement were seen in lower extremity muscle strength (prospective analysis) and walking speed (post-hoc analysis) in the Fampridine-SR group compared to placebo (unadjusted p-values of 0.01 and 0.03, respectively). There were no significant differences in other MSFC measure or fatigue scores.

Conclusions Future studies should employ doses up to 20 mg twice daily with lower extremity strength and walking speed as potential outcome measures. Multiple Sclerosis 2007; 13: 357-368. http://msj.sagepub.com

Key Words: 4-aminopyridine • clinical trial • Fampridine-SR • multiple sclerosis • safety

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. R Korenke, M. P Rivey, and D. R Allington Sustained-Release Fampridine for Symptomatic Treatment of Multiple Sclerosis Ann. Pharmacother., October 1, 2008; 42(10): 1458 - 1465. [Abstract] [Full Text] [PDF]